STOCK TITAN

MEI Pharma Inc - MEIP STOCK NEWS

Welcome to our dedicated news page for MEI Pharma (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on MEI Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MEI Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MEI Pharma's position in the market.

Rhea-AI Summary
MEI Pharma, Inc. reported positive results for the three and six months ended December 31, 2023. The company highlighted ongoing clinical studies for voruciclib and ME-344, with strong investigator support. MEI presented data from Phase 1 trials at major conferences. Financially, MEI had $59.5 million in cash with no debt, and operational expenses decreased due to program changes. The company expects to report more clinical data in the near future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
earnings
-
Rhea-AI Summary
MEI Pharma, Inc. (Nasdaq: MEIP) has announced the design of the ongoing Phase 1b study of ME-344, a mitochondrial oxidative phosphorylation (OXPHOS) inhibitor, in combination with bevacizumab (Avastin®) in refractory metastatic colorectal cancer patients. The study will be presented at the 2024 ASCO Gastrointestinal Cancers Symposium. The combination is intended to create metabolic synthetic lethality to address known resistance mechanisms to standard-of-care cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.7%
Tags
conferences clinical trial
-
Rhea-AI Summary
MEI Pharma, Inc. (Nasdaq: MEIP) announced clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, alone and in combination with venetoclax in patients with acute myeloid leukemia or B-cell malignancies. Safety profile observed suggests no overlapping toxicity. Initial results from correlative studies demonstrate on-target reductions in Mcl-1 and RNA Pol II p-S2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
clinical trial
Rhea-AI Summary
MEI Pharma (MEIP) reports strong clinical study support for drug candidates voruciclib and ME-344, with data from Phase 1 trials expected in 2024. Recent highlights include dosing of the first patient in a Phase 1b study for ME-344, and an abstract presentation at the ASH Annual Meeting. Financially, the company recognized revenue of $65.3 million for the quarter ended September 30, 2023, and reported net income of $56.4 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
earnings
-
Rhea-AI Summary
MEI Pharma, Inc. (MEIP) to present at Stifel 2023 Healthcare Conference, offering business update. Investors invited to live webcast on November 15 at 8:35 AM Eastern Time. Replay available on www.meipharma.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
conferences
-
Rhea-AI Summary
MEI Pharma, Inc. (Nasdaq: MEIP) has announced a special cash dividend of $1.75 per share of common stock, payable on December 6, 2023. The dividend will be characterized for tax purposes as a return of capital to shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.57%
Tags
dividends
Rhea-AI Summary
MEI Pharma announced that clinical data from the Phase 1 study of voruciclib will be presented at the ASH Annual Meeting. The study evaluates the CDK9 inhibitor alone and in combination with venetoclax in patients with AML or B-cell malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
-
Rhea-AI Summary
MEI Pharma and Anson Funds and Cable Car Capital have entered into a cooperation agreement. MEI Pharma plans to pay a dividend of $1.75 per share to stockholders and authorize a second return of capital of approximately $9.33 million. The company has appointed two directors designated by Anson and Cable Car and formed a Capital Allocation Committee. Anson and Cable Car have agreed to withdraw their consent solicitation and vote for the company's director nominees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
none
-
Rhea-AI Summary
MEI Pharma files definitive consent revocation statement and urges stockholders to disregard Anson Advisors and Cable Car Capital's consent solicitation materials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
Rhea-AI Summary
MEI Pharma adopts a limited-duration stockholder rights plan in response to Anson Advisors and Cable Car Capital accumulating approximately 19.9% of outstanding shares. The plan aims to protect stockholders' long-term value and prevent a self-interested group from taking control. The plan becomes exercisable if any person acquires 20% or more of the company's outstanding common stock. The Rights Plan is effective immediately and will expire on September 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
MEI Pharma Inc

Nasdaq:MEIP

MEIP Rankings

MEIP Stock Data

28.32M
4.94M
0.55%
47.52%
0.15%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About MEIP

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.